BNP Paribas Financial Markets Has $44,000 Stock Holdings in Celcuity Inc. (NASDAQ:CELC)

BNP Paribas Financial Markets reduced its holdings in Celcuity Inc. (NASDAQ:CELC - Free Report) by 92.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,325 shares of the company's stock after selling 41,785 shares during the period. BNP Paribas Financial Markets' holdings in Celcuity were worth $44,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in CELC. SG Americas Securities LLC increased its position in shares of Celcuity by 83.2% during the fourth quarter. SG Americas Securities LLC now owns 14,646 shares of the company's stock valued at $192,000 after purchasing an additional 6,651 shares during the period. Bleakley Financial Group LLC bought a new stake in shares of Celcuity during the fourth quarter valued at approximately $146,000. Rhumbline Advisers increased its position in shares of Celcuity by 20.6% during the fourth quarter. Rhumbline Advisers now owns 38,755 shares of the company's stock valued at $507,000 after purchasing an additional 6,625 shares during the period. New York State Common Retirement Fund increased its position in shares of Celcuity by 14.9% during the fourth quarter. New York State Common Retirement Fund now owns 28,391 shares of the company's stock valued at $372,000 after purchasing an additional 3,682 shares during the period. Finally, Bank of New York Mellon Corp increased its position in shares of Celcuity by 20.3% during the fourth quarter. Bank of New York Mellon Corp now owns 64,125 shares of the company's stock valued at $839,000 after purchasing an additional 10,828 shares during the period. 63.33% of the stock is owned by institutional investors.

Celcuity Price Performance

CELC stock traded up $1.27 during trading on Friday, hitting $13.05. The company had a trading volume of 188,195 shares, compared to its average volume of 290,888. The company has a fifty day moving average price of $10.39 and a two-hundred day moving average price of $11.30. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65. The company has a market cap of $494.15 million, a P/E ratio of -5.00 and a beta of 0.37. Celcuity Inc. has a fifty-two week low of $7.58 and a fifty-two week high of $19.77.

Celcuity (NASDAQ:CELC - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.86) EPS for the quarter, beating the consensus estimate of ($0.95) by $0.09. Equities research analysts expect that Celcuity Inc. will post -2.62 earnings per share for the current fiscal year.

Analyst Ratings Changes

CELC has been the topic of a number of research reports. HC Wainwright restated a "buy" rating and set a $27.00 price objective on shares of Celcuity in a research report on Monday, May 19th. Needham & Company LLC reaffirmed a "buy" rating and issued a $29.00 price target on shares of Celcuity in a research note on Thursday, May 15th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $30.80.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.